Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo 

Slides:



Advertisements
Similar presentations
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
Advertisements

Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.
Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Stephen R. Broderick, MD, MPHS 
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo  Jessica A. Yu, MD, David Mauchley, MD, Howard Li, MD, Xianzhong.
Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
Lung cancer screening: No more excuses
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase.
Interventional radiology suite or hybrid operating room: Which is the best for lung nodule localization?  Robert B. Cameron, MD  The Journal of Thoracic.
The days of future past  Neel K. Ranganath, MD, Aubrey C. Galloway, MD 
Ground glass opacity of the lung: The veil that needs lifting
Circulating tumor DNA: Solid data from liquid biopsies
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models  Josephine Hai, PhD, Shingo Sakashita,
Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer 
John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N
How should we treat air leaks?
Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial  Stacey.
New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum  Martin Czerny, MD, MBA  The Journal.
Chadrick E Denlinger, MD, Michael D Keller, BS, Marty W Mayo, PhD, R
The lord of the rings  Antonio Miceli, MD, PhD 
Is tissue the issue?  Brian E. Louie, MD, MHA, MPH, FRCSC, FACS 
Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base  Kathryn E. Engelhardt,
STAT3, Cten, and lung cancer: Simultaneous excitement and caution
Yang Zhang, MD, Haiquan Chen, MD, PhD 
Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.
The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery  Vinay Badhwar, MD  The Journal of Thoracic and.
It's not “just a shunt” but sometimes it should be…
Bartley P. Griffith, MD, FACS, FRCS 
Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective  Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.
Military surgeons just want to have fun
A first start for lung transplantation?
Stephen R. Broderick, MD, MPHS 
Chadrick E. Denlinger, MD, Brian K. Rundall, DO, Michael D
Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD 
Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow?  Jules Lin, MD  The Journal of Thoracic and Cardiovascular.
Attachment disorder in thoracoabdominal surgery
Video-assisted resection for lung cancer results in fewer complications  Lunxu Liu, PhD, MD, FRCS  The Journal of Thoracic and Cardiovascular Surgery 
We are the company we keep: The importance of the tumor microenvironment  Sai Yendamuri, MD, FACS  The Journal of Thoracic and Cardiovascular Surgery 
Volume 18, Issue 3, Pages (March 2010)
Passing the torch The Journal of Thoracic and Cardiovascular Surgery
Functional tricuspid pathology: To treat or not to treat
The origins of open heart surgery at the University of Minnesota 1951 to 1956  Richard A. DeWall, MD  The Journal of Thoracic and Cardiovascular Surgery 
Bryan M. Burt, MD  The Journal of Thoracic and Cardiovascular Surgery 
Early extubation after cardiac surgery: The evolution continues
The Journal of Thoracic and Cardiovascular Surgery
Discussion The Journal of Thoracic and Cardiovascular Surgery
The future of cardiac surgery training: A survival guide
Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD 
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
“The more things change…”: The challenges ahead
Commentary: Judgment day: Should you add atrial fibrillation ablation?
Toward a more rational approach in treating type B aortic dissection
Toll-like receptor 4 inhibition attenuates ischemia-reperfusion injury in rats: Will it work in human beings?  Chadrick E. Denlinger, MD  The Journal.
Aritoshi Hattori, MD, Kenji Suzuki, MD 
Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery  Raja M. Flores, MD  The Journal.
Preoperative PFTs: The answer is blowing in the wind
Who should decide margin length in pulmonary excision of lung cancer?
Samuel Kim, MD  The Journal of Thoracic and Cardiovascular Surgery 
Journal changes and initiatives
Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer  Chengwu.
Deciding how much to pay for effective care
Presentation transcript:

Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo  Chadrick E. Denlinger, MD, Brian K. Rundall, DO, David R. Jones, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 130, Issue 5, Pages 1422-1429 (November 2005) DOI: 10.1016/j.jtcvs.2005.06.051 Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 A, NSCLC cells were treated with nothing, butyrate, LY, or both drugs. NF-κB–dependent transcriptional activity was determined by (A) Gal4-p65 luciferase reporter genes and (B) transcription of MnSOD, Bfl/A1, and cIAP-2 by RT-PCR. C, Identically treated cells were analyzed by Western blotting for the proteins Akt, phospho-Akt, acetyl-H3, and phospho-GSKβ. (†P ≤ .006 vs no treatment, and * P ≤ .02 vs butyrate.) RLU, Relative light unit. The Journal of Thoracic and Cardiovascular Surgery 2005 130, 1422-1429DOI: (10.1016/j.jtcvs.2005.06.051) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 NSCLC cells were treated with nothing, butyrate (500 μmol/L), LY (25 μmol/L), or both drugs, and apoptosis was measured by (A) caspase-3 activity and (B) DNA fragmentation. C, NSCLC cells were treated as above, and survival was determined by clonogenic survival (survival expressed relative to untreated controls). (†P ≤ .002 and *P ≤ .013 vs all other treatment conditions.) The Journal of Thoracic and Cardiovascular Surgery 2005 130, 1422-1429DOI: (10.1016/j.jtcvs.2005.06.051) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 NSCLC xenografts were treated with nothing, butyrate (8 mg/mL in drinking water), LY (100 mg/kg intraperitoneally twice weekly), or both drugs, and tumors were measured every other day. Volumes were calculated and expressed as relative tumor growth (V/Vo) ± standard error of mean (P ≤ .005). The Journal of Thoracic and Cardiovascular Surgery 2005 130, 1422-1429DOI: (10.1016/j.jtcvs.2005.06.051) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 A, Xenografts were harvested and apoptosis was determined by TUNEL analysis. B, Western blots were performed on xenografts for phospho-Akt, Akt, acetyl-histone H3, MnSOD, and RNA pol II. The Journal of Thoracic and Cardiovascular Surgery 2005 130, 1422-1429DOI: (10.1016/j.jtcvs.2005.06.051) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions